Newsroom 2006
Attention Business/Financial Editors:
Neurochem to present at UBS Global Life Sciences Conference
LAVAL, QC, Sept. 21 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX:
NRM) announced today that on Tuesday, September 26, 2006, Dr. Francesco
Bellini, Chairman, President and Chief Executive Officer, will present
Neurochem's overall progress to date on its various drug development programs
and the latest regulatory developments at the UBS Global Life Sciences
Conference to be held at the Grand Hyatt New York, in New York (N.Y.). The
presentation will take place at 2:00 P.M. ET, in Ballroom B.
The corporate presentation will be available on the Company's Web site at
http://www.neurochem.com/Investor.htm#Presentation following Dr. Bellini's
speech.
A live audio Web cast of Neurochem's presentation can be accessed at
www.ibb.ubs.com. A replay of the presentation will begin three (3) hours after
the actual presentation time, and will be available until October 3, 2006.
About Neurochem
Neurochem is focused on the development and commercialization of
innovative therapeutics to address critical unmet medical needs. Eprodisate
(Kiacta(TM)) is currently being developed for the treatment of AA amyloidosis,
for which the Company received an approvable letter from the FDA in August
2006. Tramiprosate (Alzhemed(TM)), for the treatment of Alzheimer's disease,
is currently in Phase III clinical trials in both North America and Europe and
tramiprosate (Cerebril(TM)), for the prevention of Hemorrhagic Stroke caused
by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.
To Contact Neurochem
For additional information on Neurochem and its drug development
programs, please call the North American toll-free number 1-877-680-4500 or
visit our Web site at www.neurochem.com.
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Neurochem's
control. Such risks include but are not limited to: the impact of general
economic conditions, general conditions in the pharmaceutical industry,
changes in the regulatory environment in the jurisdictions in which Neurochem
does business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation, as well as other risks
disclosed in public filings of Neurochem. Consequently, actual future results
may differ materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue reliance, if
any, on the forward-looking statements included in this news release. These
statements speak only as of the date made and Neurochem is under no obligation
and disavows any intention to update or revise such statements as a result of
any event, circumstances or otherwise. Please see the Annual Information Form
for further risk factors that might affect the Company and its business.
For further information: Lise Hébert, Ph.D., Vice President, Corporate
Communications, (450) 680-4570, lhebert@neurochem.com
